- The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis
- This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara® (ustekinumab) and Humira® (adalimumab) in achieving skin clearance at week 16
PR Newswire
BRUSSELS, Sept. 22, 2020